Navigation Links
AtriCure to Participate at the Thomas Weisel Partners Healthcare Conference and the UBS Global Life Sciences Conference in September
Date:8/25/2008

WEST CHESTER, Ohio, Aug. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during September:

-- The Thomas Weisel Partners Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3, 2008. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 10:55 a.m. Eastern time.

-- The UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City on Thursday, September 25, 2008. Mr. Drachman is scheduled to present at 8:30 a.m. Eastern time.

Both presentations will be available live and by replay for 30 days following the presentations at http://www.atricure.com/Investor_Relations .

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
4. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
7. AtriCure Ranked 80th in Deloittes Technology Fast 500
8. AtriCure Reports Third Quarter 2007 Financial Results
9. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
10. AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
11. AtriCure Appoints Mark A. Collar to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... Pregnancy Awareness Month offers a great time to get familiar ... you are ready to have a baby, it’s best to get started before age ... your Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a ... designed to automate and improve the rapid diagnosis, triage and admission of patients ... platform, application, and mobile experience for the first time at GENBAND’s Perspectives16 conference. ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development ... Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to ... Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate payment ... drugs while preserving care provided to beneficiaries. The webinar will review the details of ...
(Date:5/2/2016)... ... 2016 , ... For many artists, the act of blending paint is based ... a science. , Using the new, highly precise METTLER TOLEDO ML204T balance to ... and meaning to his works. What’s more, it has allowed him to recreate these ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 Glycotope GmbH, a ... announces the appointment of Dr. Alfredo Zurlo ... an oncologist with many years clinical experience and a ... His last role was at Mologen AG where he ... Board. Previously Dr. Zurlo held various positions at F ...
(Date:4/28/2016)... 2016   Click here for supplemental information ... DPLO), the nation,s largest independent specialty pharmacy, announced ... to acquire Valley Campus Pharmacy, Inc., doing business ... specialty pharmacy that provides individualized patient care, based ... In 2015, TNH generated approximately $400 million in ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
Breaking Medicine Technology: